Improper Dose In Phase II Trials Can ‘Make Or Break’ Drug Program, FDA’s Stein Says

Director of the US FDA’s Office of New Drugs says there will be a greater focus on identifying the optimal dose before a drug candidate advances into Phase III trials, but the problem is not limited to oncology, the target of Project Optimus.